Page 61 - 83_02

Latency-reversing agents as part of the strategies to cure HIV infection 223

50. Toll-like Receptor 9 Enhancement of Antiviral
Immunity in Chronic HIV-1 Infection: a Phase Ib/IIa
Trial. In: ClinicalTrials.gov. Bethesda (MD): National
Library of Medicine (US). Registered on April 30,
2015. NLM Identifier: NCT02443935.

51. Garrido C, Spivak AM, Soriano-Sarabia N, et al. HIV
Latency-Reversing Agents Have Diverse Effects on
Natural Killer Cell Function. Front Immunol. 2016; 7:
356.

52. Schmidt M, Hagner N, Marco A, et al. Design and
Structural Requirements of the Potent and Safe TLR-9
Agonistic Immunomodulator MGN1703. Nucleic
Acid Therapeutics 2015; 25: 130-40.

53. Halper-Stromberg A, Nussenzweig MC. Towards
HIV-1 remission: potential roles for broadly
neutralizing antibodies. J Clin Invest. 2016; 126: 415-
23.

54. a) Day CL, Kaufmann DE, Kiepiela P, et al. PD-1
expression on HIV-specific T cells is associated with
T-cell exhaustion and disease progression. Nature
2006; 443: 350-4. b) Eron JJ, Gay C, Bosch RJ, et al.
Safety, immunologic and virologic activity of anti-
PD-L1 in HIV-1 participants on ART. Abstract 25. In:
Conference on Retroviruses and Opportunistic
Infections CROI 2016, 22-25 February 2016, Boston,
USA.

55. a) Pandeló D, Bartholomeeusen K, Delvecchio R, et al.
Reactivation of latent HIV-1 by new semi-synthetic
ingenol esters. Virology 2014; 462-463: 328-39. b)
Laird GM, Bullen CK, Rosenbloom DIS, et al. Ex
vivo analysis identifies effective HIV-1 latency–
reversing drug combinations. J Clin Invest. 2015; 125:
1901-12. c) Darcis G, Kula A, Bouchat S, et al. An in-
depth comparison of latency-reversing agent
combinations in various in vitro and ex vivo HIV-1
latency models identified Bryostatin-1 + JQ1 and
Ingenol-B + JQ1 to potently reactivate viral gene
expression. PLoS Pathog. 2015; 11: e1005063.

56. a) Siliciano JD, Siliciano RF. Recent developments in
the effort to cure HIV infection: going beyond N = 1.
J Clin Invest. 2016; 126: 409-14. b) Garcia JV. In vivo
platforms for analysis of HIV persistence and
eradication. J Clin Invest. 2016; 126: 424-31.

@Real Academia Nacional de Farmacia. Spain